The BD SurePath™ liquid-based Pap test provides advantages over conventional Pap smears and other liquid-based cytology (LBC) tests, resulting in greater disease detection.
true
{"AlternateComparison":false,"RelatedProducts":false,"Specification":true,"FeatureBenefit":false}
BD SurePath™
BD SurePath™ liquid-based Pap test
![Icon to close thank you modal]()
ROVERS CERVEX BRUSHES, 500 EA
Support
Becton, Dickinson and Company
0124-4124300
bd_india@bd.com
Contact Us
Thank you for contacting our sales team!
A sales representive will get in touch with you shortly.
Address
6th Floor Signature Tower - B, South City I, NH 8 Gurgaon, 122001, Haryana
- Overview
- Specifications
- eIFUs and Resources
true
FEATURE AND BENEFIT CARDS NOT AVAILABLE
FEATURE AND BENEFIT CARDS NOT AVAILABLE
GTIN - Shelfpack
18719189246480
500
GTIN - Bag
08719189246483
25
GTIN - Each
00382904914615
1
Quantity - Shelfpack
500
Shelf Life (Days)
0
GTIN
| GTIN - Shelfpack | 18719189246480 | 500 |
| GTIN - Bag | 08719189246483 | 25 |
| GTIN - Each | 00382904914615 | 1 |
Packaging
| Quantity - Shelfpack | 500 |
Storage and Handling
| Shelf Life (Days) | 0 |
- BD PrepStain™ slide processor: direct-to-vial study population [product insert]. Franklin Lakes, NJ: Becton, Dickinson and Company; 2016.
- Fremont-Smith M, Marino J, Griffin B, Spencer L, Bolick D. Comparison of the Surepath liquid-based Papanicolaou smear with the conventional Papanicolaou smear in a multisite direct-to-vial study. Cancer. 102:269-279.
- Nygård JF, Sauer T, Nygård M, Skare GB, Thoresen S Ø. CIN 2/3 and cervical cancer in an organised screening programme after an unsatisfactory or a normal Pap smear: a seven-year prospective study of the Norwegian population-based screening programme. J Med Screen. 2004;11(2):70-76.
- Nance KV. Evolution of Pap testing at a community hospital: a ten year experience. Diagn Cytopathol. 2007:35(3):148-153.
true
true